A5090882926- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Hormonal Regulation and Hypertension
- Renin-Angiotensin System Studies
- Microtubule and mitosis dynamics
- Cancer-related gene regulation
- Biofield Effects and Biophysics
- Hybrid Renewable Energy Systems
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Cytokine Signaling Pathways and Interactions
- Cancer Cells and Metastasis
- Traditional Chinese Medicine Studies
- DNA Repair Mechanisms
- Chronic Kidney Disease and Diabetes
- Thyroid Disorders and Treatments
- NF-κB Signaling Pathways
Shanghai Medical College of Fudan University
2023-2025
Fudan University
2023-2025
Fudan University Shanghai Cancer Center
2023-2025
Jiangsu Province Hospital
2023-2024
Nanjing Medical University
2019-2024
Jiangsu Cancer Hospital
2023-2024
Xian Yang Central Hospital
2023
Chengdu University of Traditional Chinese Medicine
2023
The First People’s Hospital of Lianyungang
2023
Second Affiliated Hospital of Chengdu University of Traditional Chinese
2022
The aim of the present study was to investigate whether androgen receptor (AR) status affects efficacy neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients, and elucidate predictive biomarkers mutations associated with pathological complete response (pCR) AR-positive TNBC patients. current retrospective cohort included 226 patients who underwent NACT. AR FOXC1 were assessed by immunohistochemistry on pretreatment biopsy specimens from 2018 2022....
Background: Cuproptosis, a newly defined regulated form of cell death, is mediated by the accumulation copper ions in cells and related to protein lipoacylation. Seven genes have been reported as key cuproptosis phenotype. Cuproptosis may be developed subsequent research target treat cancer, such breast cancer. Long-noncoding RNA (lncRNA) has proved play vital role regulating biological process However, lncRNAs poorly studied. Methods: Based on TCGA (The Cancer Genome Atlas) database...
Aims Human epidermal growth factor receptor 2 (HER2)-positive patients with breast cancer may have different HER2/CEP17 ratios and HER2 copy numbers, inconsistent responses to anti-HER2 neoadjuvant chemotherapy (NACT). Our study aimed explore the relationship between fluorescence in situ hybridisation (FISH) patterns HER2-positive NACT. Methods 527 invasive who received NACT from 2015 2022 were included divided into three groups by FISH results, namely group A: HER2/CEP17<2.0 numbers...
Abstract Background Breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough progress of novel anti-HER2 antibody-drug conjugates. HER2 examined in patients HER2-low BC and their distant metastases this study, so as further clarify dynamic characteristics status process disease progression. Methods Patients diagnosed breast (defined IHC1+ or IHC2+/ISH-) between 2012 2021 were included study. We evaluated...
Breast cancer is a global public health concern with high mortality rates, necessitating the development of innovative treatment strategies. PARP inhibitors have shown efficacy in certain patient populations, but their application largely limited to cancers homologous recombination deficiency. Here, we identified suppression FANCI as therapeutic strategy enhance breast cancer. Elevated expression was associated poor prognosis and increased cell proliferation migration. interacted PARP1,...
Abstract Mesangioproliferative glomerulonephritis (MsPGN) is characterized by the proliferation of glomerular mesangial cells (GMCs) and accumulation extracellular matrix (ECM), followed glomerulosclerosis renal failure patients. Although our previous studies have demonstrated that sublytic C5b‐9 complex formed on GMC membrane could trigger ECM expansion rat Thy‐1 nephritis (Thy‐1N) as an animal model MsPGN, their mechanisms are still not fully elucidated. In present studies, we found levels...
Context.— Breast cancer with low (1%–10%) estrogen receptor (ER) expression (ER–low positive) constitutes a small portion of invasive breast cancers, and the treatment strategy for these tumors remains debatable. Objective.— To characterize features outcomes ER–low positive patients, clarify clinical significance FOXC1 SOX10 in positive/HER2-negative tumors. Design.— Among 9082 patients diagnosed primary cancer, clinicopathologic those were characterized. mRNA levels analyzed cases from...
Abstract While polyADP-ribose polymerase (PARP) inhibitors have made advancements in the treatment of breast cancer, challenges such as chemotherapy resistance and limited application persist. Fanconi AnemiaComplementation Group I (FANCI), a DNA repair protein associated with cancer development, represents potential target for novel combination therapeutic strategies. However, role FANCI its impact on efficacy PARP require further investigation. In our study, we analyzed expression tissues...
Tumor metastasis involves a series of complex processes and is major challenge in clinical treatment. The cooperation epigenetic modifications metabolic adaptations endows tumor cells with dynamic for survival variable environments, which crucial worth exploring depth. In this study, we found IGF2BP3 could link modification adaptation promoting autophagy-mediated triple-negative breast cancer (TNBC) metastasis. As TNBC specifically high expressed N6-methyladenosine (m6A) binding protein,...
<p>Figure S3 shows FANCI overexpression facilitates the proliferation of breast cancer cells.</p>
<p>Table S1-4 contain the specific sequences and information of Primers used for Quantitative RT-PCR, shRNA, siRNA, Flag-tagged plasmids.</p>
<div>Abstract<p>Breast cancer is a global public health concern with high mortality rates, necessitating the development of innovative treatment strategies. PARP inhibitors have shown efficacy in certain patient populations, but their application largely limited to cancers homologous recombination deficiency. Here, we identified suppression FANCI as therapeutic strategy enhance breast cancer. Elevated expression was associated poor prognosis and increased cell proliferation...
<p>Figure S5 presents a comprehensive analysis of the interaction between FANCI and PARP1.</p>
<p>Figure S4 shows FANCI overexpression enhances breast cancer cell migration ability.</p>